Cwm LLC Has $3.79 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Cwm LLC trimmed its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 5.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,569 shares of the company’s stock after selling 1,757 shares during the quarter. Cwm LLC owned 0.11% of Krystal Biotech worth $3,792,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of KRYS. Vanguard Group Inc. raised its stake in shares of Krystal Biotech by 40.7% in the third quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock valued at $278,416,000 after purchasing an additional 693,852 shares in the last quarter. Jennison Associates LLC raised its stake in Krystal Biotech by 485.0% during the third quarter. Jennison Associates LLC now owns 340,849 shares of the company’s stock worth $39,538,000 after acquiring an additional 282,583 shares in the last quarter. Fred Alger Management LLC raised its stake in Krystal Biotech by 4,608.6% during the third quarter. Fred Alger Management LLC now owns 167,485 shares of the company’s stock worth $19,428,000 after acquiring an additional 163,928 shares in the last quarter. TimesSquare Capital Management LLC acquired a new position in Krystal Biotech during the third quarter worth $14,272,000. Finally, Schonfeld Strategic Advisors LLC raised its stake in Krystal Biotech by 356.8% during the third quarter. Schonfeld Strategic Advisors LLC now owns 83,635 shares of the company’s stock worth $9,702,000 after acquiring an additional 65,325 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

KRYS has been the subject of several recent analyst reports. Citigroup increased their price objective on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. William Blair reiterated an “outperform” rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. Stifel Nicolaus restated a “buy” rating and set a $204.00 target price (up previously from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Guggenheim increased their target price on Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $200.00 target price on shares of Krystal Biotech in a report on Monday. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $171.00.

Krystal Biotech Stock Down 1.8 %

Krystal Biotech stock opened at $159.05 on Thursday. The business’s 50-day simple moving average is $162.61 and its 200 day simple moving average is $131.15. The stock has a market cap of $4.53 billion, a price-to-earnings ratio of 1,988.37 and a beta of 0.85. Krystal Biotech, Inc. has a 12-month low of $82.09 and a 12-month high of $189.97.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.82. The firm had revenue of $42.14 million during the quarter, compared to the consensus estimate of $27.43 million. During the same quarter in the prior year, the business earned ($1.25) EPS. As a group, sell-side analysts expect that Krystal Biotech, Inc. will post 1.89 EPS for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Kathryn Romano sold 8,087 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $136.91, for a total value of $1,107,191.17. Following the completion of the transaction, the chief accounting officer now directly owns 12,556 shares in the company, valued at approximately $1,719,041.96. The disclosure for this sale can be found here. Insiders have sold a total of 38,087 shares of company stock worth $6,210,591 over the last 90 days. Insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).